Current trends in West Nile virus vaccine development

Ian J. Amanna, Mark K. Slifka

    Research output: Contribution to journalReview articlepeer-review

    40 Scopus citations


    West Nile virus (WNV) is a mosquito-borne flavivirus that has become endemic in the United States. From 1999-2012, there have been 37088 reported cases of WNV and 1549 deaths, resulting in a 4.2% case-fatality rate. Despite development of effective WNV vaccines for horses, there is no vaccine to prevent human WNV infection. Several vaccines have been tested in preclinical studies and to date there have been eight clinical trials, with promising results in terms of safety and induction of antiviral immunity. Although mass vaccination is unlikely to be cost effective, implementation of a targeted vaccine program may be feasible if a safe and effective vaccine can be brought to market. Further evaluation of new and advanced vaccine candidates is strongly encouraged.

    Original languageEnglish (US)
    Pages (from-to)589-608
    Number of pages20
    JournalExpert Review of Vaccines
    Issue number5
    StatePublished - May 2014


    • West Nile virus
    • antibody
    • epidemiology
    • flaviviruses
    • immunity
    • immunocompromised
    • neurotropic
    • vaccination

    ASJC Scopus subject areas

    • Immunology
    • Molecular Medicine
    • Pharmacology
    • Drug Discovery


    Dive into the research topics of 'Current trends in West Nile virus vaccine development'. Together they form a unique fingerprint.

    Cite this